Clinical Scorecard: Rethinking Drops in the Interventional Era
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Use of topical drops alongside interventional treatments like laser and MIGS to enhance outcomes. |
| Target Population | Patients with glaucoma, particularly those with severe ocular surface disease. |
| Care Setting | Ophthalmology clinics and surgical settings. |
Key Highlights
- 74% of ASCRS members use drops as initial therapy for glaucoma.
- Minimal instillation drop strategy (MIDS) emphasizes targeted use of medications.
- Preservative-free formulations are available to reduce ocular surface disease.
- Fixed combinations can improve efficacy and simplify treatment regimens.
- Adherence to medication is critical for visual outcomes.
Guideline-Based Recommendations
Diagnosis
- Consider individual patient factors and procedural plans in glaucoma management.
Management
- Utilize drops strategically to support procedural interventions.
Monitoring & Follow-up
- Assess tolerability and adherence regularly to optimize treatment.
Risks
- Cumulative exposure to preservatives can negatively affect ocular surface and surgical outcomes.
Patient & Prescribing Data
Patients with glaucoma, especially those with severe ocular surface disease.
Use drops as supplements or bridge therapies rather than primary treatments.
Clinical Best Practices
- Implement the TEAM approach: Tolerability, Efficacy, Adherence, Mechanism of action.
- Simplify regimens to improve adherence and reduce drop burden.
- Explore compatibility of drops with specific procedural interventions.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.